Glaucoma Eye Drops and Supplements: Supporting the Eye-Nerve-Brain Axis

Understanding Glaucoma

Glaucoma is a group of progressive optic neuropathies characterised by the gradual loss of retinal ganglion cells (RGCs) and their axons, which form the optic nerve. It is the leading cause of irreversible blindness worldwide, affecting over 700,000 people in the UK — with an estimated further 300,000 undiagnosed.

What makes glaucoma particularly insidious is that it is largely asymptomatic in its early stages. Peripheral vision is lost first, and by the time a patient notices visual changes, up to 40% of RGCs may already be irreversibly lost. This makes regular eye examinations — including optic nerve assessment and visual field testing — essential for early detection.

Types of Glaucoma

• Primary open-angle glaucoma (POAG) — the most common form in the UK, accounting for around 90% of cases. The drainage angle of the eye remains open, but aqueous humour drains too slowly, causing a gradual rise in intraocular pressure (IOP). Progression is slow and painless.
• Angle-closure glaucoma — the drainage angle becomes blocked, causing a rapid, painful rise in IOP. Acute angle-closure is an ophthalmic emergency. More common in people of East Asian descent and those who are hyperopic (long-sighted).
• Normal-tension glaucoma (NTG) — optic nerve damage occurs despite IOP within the statistically normal range (10–21 mmHg). Vascular dysregulation and impaired ocular blood flow are thought to play a significant role, making this subtype particularly relevant to nutritional and neuroprotective strategies.
• Secondary glaucomas — caused by identifiable conditions such as pseudoexfoliation syndrome, pigment dispersion, uveitis, or trauma.

The Role of Intraocular Pressure

Elevated IOP is the primary modifiable risk factor for glaucoma progression. The eye continuously produces aqueous humour — a clear fluid that nourishes the lens and cornea — which drains through the trabecular meshwork at the drainage angle. When outflow is impaired, IOP rises, increasing mechanical stress on the optic nerve head and compressing the lamina cribrosa, through which RGC axons pass.

However, IOP is not the whole story. Normal-tension glaucoma demonstrates that optic nerve vulnerability, vascular factors, and neuroinflammation are equally important drivers of RGC loss — which is why neuroprotective strategies are an active area of research.

Clinical Treatments: Lowering IOP

All currently approved glaucoma treatments work by reducing IOP. The goal is to establish a personalised target IOP — a pressure at which further optic nerve damage is unlikely — and maintain it consistently.

Eye Drops (First-Line Medical Treatment)

Topical IOP-lowering drops are the mainstay of glaucoma management:

• Prostaglandin analogues (latanoprost, bimatoprost, travoprost) — first-line agents that increase uveoscleral outflow. Highly effective, once-daily dosing, well tolerated. May cause iris pigmentation and eyelash changes with long-term use.
• Beta-blockers (timolol, betaxolol) — reduce aqueous production. Contraindicated in asthma, COPD, and certain cardiac conditions.
• Carbonic anhydrase inhibitors (dorzolamide, brinzolamide) — reduce aqueous production. Often used in combination drops (e.g., Cosopt, Azarga).
• Alpha-2 agonists (brimonidine) — reduce aqueous production and increase uveoscleral outflow. Also has some neuroprotective properties in preclinical models.
• Rho kinase inhibitors (netarsudil) — a newer class that increases trabecular outflow. Used when other agents are insufficient or not tolerated.

Laser Treatment

• Selective laser trabeculoplasty (SLT) — NICE now recommends SLT as a first-line treatment option for POAG and ocular hypertension. It uses short pulses of low-energy laser to stimulate the trabecular meshwork, improving drainage. Effective in approximately 75–80% of patients, with effects lasting 3–5 years and repeatable.
• Laser peripheral iridotomy (LPI) — used in angle-closure glaucoma to create a small opening in the iris, relieving pupillary block.

Surgery

• Trabeculectomy — the gold-standard surgical procedure, creating a new drainage channel (bleb) beneath the conjunctiva. Highly effective but carries risks including infection, hypotony, and bleb failure.
• Minimally invasive glaucoma surgery (MIGS) — a growing category of procedures (iStent, Hydrus, OMNI, XEN gel stent) offering a more favourable safety profile, often performed in conjunction with cataract surgery.

Beyond IOP: The Eye-Nerve-Brain Axis

Emerging research increasingly frames glaucoma as a neurodegenerative disease with parallels to Alzheimer's and Parkinson's disease. RGC loss in glaucoma shares pathological features with other neurodegenerative conditions — including mitochondrial dysfunction, neuroinflammation, glutamate excitotoxicity, and impaired axonal transport.

This has shifted scientific interest towards neuroprotective strategies that target the optic nerve and visual pathway independently of IOP — an area where nutritional supplementation shows genuine promise.

Nutritional Support for Glaucoma: The Evidence

Citicoline (CDP-Choline)

Citicoline is one of the most studied neuroprotective agents in glaucoma. It is a precursor to phosphatidylcholine, a key component of neuronal cell membranes, and supports mitochondrial function, acetylcholine synthesis, and retinal ganglion cell survival. Multiple randomised controlled trials have demonstrated that citicoline supplementation — both oral and intramuscular — improves visual field indices and pattern electroretinogram (PERG) amplitude in glaucoma patients, suggesting genuine neuroprotective activity at the level of the RGC and visual cortex.

Coenzyme Q10 (CoQ10)

Mitochondrial dysfunction is a key driver of RGC apoptosis in glaucoma. CoQ10 is an essential component of the mitochondrial electron transport chain and a potent antioxidant. Preclinical studies demonstrate that CoQ10 protects RGCs from oxidative stress and IOP-induced damage. Clinical studies have shown improvements in PERG amplitude with CoQ10 supplementation, consistent with preserved RGC function.

Magnesium

Magnesium has vasodilatory properties and plays a role in regulating ocular blood flow — particularly relevant in normal-tension glaucoma, where vascular dysregulation is a key pathogenic mechanism. Clinical studies have shown that magnesium supplementation improves peripheral vasospasm and visual field indices in NTG patients with vasospastic tendencies.

Lutein and Zeaxanthin

Beyond their established role in macular health, lutein and zeaxanthin are present in the optic nerve and have antioxidant and anti-inflammatory properties relevant to RGC protection. Epidemiological data suggest higher macular pigment optical density (MPOD) is associated with better visual function in glaucoma.

Ginkgo Biloba

Ginkgo biloba extract has vasodilatory, antioxidant, and neuroprotective properties. Several small RCTs have demonstrated improvements in visual field parameters in NTG patients, attributed to improved ocular blood flow and direct neuroprotective effects on RGCs.

Omega-3 Fatty Acids

DHA is a structural component of RGC membranes and has anti-inflammatory and neuroprotective properties. Observational studies suggest higher omega-3 intake is associated with reduced glaucoma risk, and preclinical data support a role for DHA in RGC survival under conditions of elevated IOP.

Ocular Express Glaucoma Supplements

We offer two specialist supplements formulated to support optic nerve health and the eye-nerve-brain axis, as a complement to prescribed IOP-lowering treatment:

GlauCap®

GlauCap® is our flagship glaucoma supplement, combining citicoline, CoQ10, magnesium, lutein, zeaxanthin, and omega-3s in clinically informed doses. It targets the eye-nerve-brain axis with comprehensive neuroprotective and vascular support.

Glaucomide

Glaucomide is a specialist vision supplement formulated to support optic nerve and eye health, providing an additional evidence-informed option for those seeking targeted nutritional support alongside their glaucoma management.

Supporting Retinal Health Alongside Glaucoma

For individuals managing glaucoma alongside diabetic eye disease or other retinal conditions, Glycoshield™ provides targeted antioxidant and vascular support for the retina. Speak with your eye care professional about whether a combined nutritional approach is appropriate for your circumstances.

Lifestyle Measures That Support Optic Nerve Health

• Regular aerobic exercise — shown to modestly reduce IOP and improve ocular blood flow; aim for 150 minutes of moderate-intensity activity per week
• Avoid prolonged head-down positions — yoga inversions and certain exercises can transiently elevate IOP
• Limit caffeine — large amounts of caffeine can cause a transient IOP spike; moderate consumption is generally acceptable
• Sleep position — sleeping with the head slightly elevated (20–30°) may reduce nocturnal IOP elevation
• Avoid tight neckwear — tight collars and ties can impair venous drainage and raise IOP
• Mediterranean diet — associated with slower glaucoma progression in observational studies

The Importance of Adherence and Monitoring

Glaucoma is a lifelong condition requiring consistent management. Non-adherence to prescribed eye drops is one of the most common reasons for disease progression — studies suggest up to 50% of glaucoma patients are non-adherent within the first year. If you find your drops difficult to instil, cause side effects, or are affecting your quality of life, discuss alternatives with your ophthalmologist rather than stopping treatment.

Regular visual field testing and optic nerve imaging (OCT) are essential to monitor for progression and adjust treatment targets accordingly.

When to Seek Urgent Care

Seek emergency eye care immediately if you experience:

• Sudden, severe eye pain
• Nausea and vomiting accompanied by eye pain
• Sudden blurred vision with halos around lights
• A red eye that does not resolve

These symptoms may indicate acute angle-closure glaucoma — an ophthalmic emergency that can cause permanent vision loss within hours if untreated.

This article is intended for informational purposes only and does not constitute medical advice. Always follow the guidance of your ophthalmologist or eye care professional regarding your glaucoma management.